Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
This text uses material from Wikipedia, licensed under CC BY-SA
Sorry, no news articles match your request
About
Phys.org™ is a leading web-based science, research and technology news service which covers a full range of topics.
Phys.org is a part of Science X network. With a global reach of over 10 million monthly readers and featuring dedicated websites for science (Phys.org), technology (Tech Xplore) and medical research (Medical Xpress), the Science X network is one of the largest online communities for science-minded people.
Read moreIdentify the news topics you want to see and prioritize an order.
Science never stops. Get notified about trending stories.